Wednesday, 14 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 13, 2025

How retail investors are shaking up Wall Street

View original at finance.yahoo.com
How retail investors are shaking up Wall Street In the last few years, retail investors have been at the heart of some of the biggest global investment stories, with unexpected meme stocks making many people wealthy…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Retail investors are a lot smarter than they are given credit for and Wall Street misses what retail does not miss.

    80% confidence
  • Retail investors in Thailand and Korea have built sophisticated investment theses on Palantir, Tesla, Opendoor, and other names.

    80% confidence
  • Retail investing flows rose by approximately 50% from 2023 to early 2025.

    80% confidence
  • Retail investors get a bad rap and are perceived as dumb money by Wall Street, which thinks they should just pile into ETFs and not try to find outperforming stocks.

    80% confidence
  • Iron and Cipher were discovered by EMJ Capital at approximately $9 and $3 respectively and were still viewed as Bitcoin miners rather than next-gen AI HPC cloud providers.

    80% confidence
  • Early retail believers in Palantir were laughed at by institutional investors when the stock was in its teens, but those institutions were crying when it hit $100 and screaming when it hit $200.

    80% confidence
  • Retail investors displayed strong FOMO around Opendoor due to missing Carvana, were bored with the Magnificent Seven, and were seeking further out on the risk curve.

    80% confidence
  • Controlling emotions as a trader is one of the most important and difficult aspects of investing, particularly during periods of high volatility and large drawdowns.

    80% confidence
  • EMJ Capital's AI model flagged Carvana at $11 and Eric Jackson invested at $15 before the stock recovered to over $400.

    80% confidence
  • Courting retail investors alone is not sufficient; a company must have an underlying compelling story.

    80% confidence
  • A fishing vessel captain in the Bering Sea invested his entire $60,000 in savings into Opendoor via Starlink while on a 10-week fishing voyage.

    80% confidence
  • Dan Ives communicates the same information publicly through social media and ETFs as he would in private institutional settings, emphasizing transparency and paying it forward.

    80% confidence
  • Retail has become a force in the market and investors must pay attention to it alongside institutional flows.

    80% confidence
  • Retail investors traveling in places like Thailand and Korea are asking questions as sophisticated as only the most advanced institutional investors would have asked two or three years ago.

    80% confidence
  • Some retail investors understand Tesla's autonomous robotic future better than institutional investors.

    80% confidence
  • Alex Karp of Palantir set the bar for courting retail investors by doing video earnings calls and taking retail questions on earnings calls, treating them as importantly as sell-side analysts.

    80% confidence
  • Retail investors have moved from the little kids' table to the adult table and are now front and center as a very important, very informed investor class.

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
How retail investors are shaking up Wall Street — Source | Via News | ViaNews EU